Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio. Under the terms of the deal, Spark will get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results